BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

404 related articles for article (PubMed ID: 16832383)

  • 1. Challenge of dose escalation in locally advanced unfavourable prostate cancer using HDR brachytherapy.
    Al-Salihi O; Mitra A; Payne H
    Prostate Cancer Prostatic Dis; 2006; 9(4):370-3. PubMed ID: 16832383
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Radiation dose escalation for localized prostate cancer: intensity-modulated radiotherapy versus permanent transperineal brachytherapy.
    Wong WW; Vora SA; Schild SE; Ezzell GA; Andrews PE; Ferrigni RG; Swanson SK
    Cancer; 2009 Dec; 115(23):5596-606. PubMed ID: 19670452
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The role of high-dose rate brachytherapy in locally advanced prostate cancer.
    Vicini FA; Vargas C; Edmundson G; Kestin L; Martinez A
    Semin Radiat Oncol; 2003 Apr; 13(2):98-108. PubMed ID: 12728439
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Technological advances in radiotherapy for the treatment of localised prostate cancer.
    Mangar SA; Huddart RA; Parker CC; Dearnaley DP; Khoo VS; Horwich A
    Eur J Cancer; 2005 Apr; 41(6):908-21. PubMed ID: 15808957
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Comparison of the outcome and morbidity for localized or locally advanced prostate cancer treated by high-dose-rate brachytherapy plus external beam radiotherapy (EBRT) versus EBRT alone.
    Fang FM; Wang YM; Wang CJ; Huang HY; Chiang PH
    Jpn J Clin Oncol; 2008 Jul; 38(7):474-9. PubMed ID: 18621848
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Hypofractionated conformal HDR brachytherapy in hormone naïve men with localized prostate cancer. Is escalation to very high biologically equivalent dose beneficial in all prognostic risk groups?
    Galalae RM; Martinez A; Nuernberg N; Edmundson G; Gustafson G; Gonzalez J; Kimming B
    Strahlenther Onkol; 2006 Mar; 182(3):135-41. PubMed ID: 16520907
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Hypofractionated boost with high-dose-rate brachytherapy and open magnetic resonance imaging-guided implants for locally aggressive prostate cancer: a sequential dose-escalation pilot study.
    Ares C; Popowski Y; Pampallona S; Nouet P; Dipasquale G; Bieri S; Ozsoy O; Rouzaud M; Khan H; Miralbell R
    Int J Radiat Oncol Biol Phys; 2009 Nov; 75(3):656-63. PubMed ID: 19250768
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Simultaneous integrated intensity-modulated radiotherapy boost for locally advanced gynecological cancer: radiobiological and dosimetric considerations.
    Guerrero M; Li XA; Ma L; Linder J; Deyoung C; Erickson B
    Int J Radiat Oncol Biol Phys; 2005 Jul; 62(3):933-9. PubMed ID: 15936580
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Combined brachytherapy with external beam radiotherapy for localized prostate cancer: reduced morbidity with an intraoperative brachytherapy planning technique and supplemental intensity-modulated radiation therapy.
    Zelefsky MJ; Nedelka MA; Arican ZL; Yamada Y; Cohen GN; Shippy AM; Park JJ; Zaider M
    Brachytherapy; 2008; 7(1):1-6. PubMed ID: 18299108
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Combined external beam radiotherapy and Pd-103 brachytherapy boost improves biochemical failure free survival in patients with clinically localized prostate cancer: results of a matched pair analysis.
    Singh AM; Gagnon G; Collins B; Niroomand-Rad A; McRae D; Zhang Y; Regan J; Lynch J; Dritschilo A
    Prostate; 2005 Jan; 62(1):54-60. PubMed ID: 15389809
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Clinical outcome in patients with prostate cancer treated with external beam radiotherapy and high dose-rate iridium 192 brachytherapy boost: a 6-year follow-up.
    Kälkner KM; Wahlgren T; Ryberg M; Cohn-Cedermark G; Castellanos E; Zimmerman R; Nilsson J; Lundell M; Fowler J; Levitt S; Hellström M; Nilsson S
    Acta Oncol; 2007; 46(7):909-17. PubMed ID: 17917823
    [TBL] [Abstract][Full Text] [Related]  

  • 12. 192Ir low dose rate brachytherapy for boosting locally advanced prostate cancers after external beam radiotherapy: a phase II trial.
    Nickers P; Coppens L; de Leval J; Jansen N; Deneufbourg JM
    Radiother Oncol; 2006 Jun; 79(3):329-34. PubMed ID: 16780976
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Dosimetric and radiobiologic comparison of 3D conformal versus intensity modulated planning techniques for prostate bed radiotherapy.
    Koontz BF; Das S; Temple K; Bynum S; Catalano S; Koontz JI; Montana GS; Oleson JR
    Med Dosim; 2009; 34(3):256-60. PubMed ID: 19647638
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Analysis of biochemical control and prognostic factors in patients treated with either low-dose three-dimensional conformal radiation therapy or high-dose intensity-modulated radiotherapy for localized prostate cancer.
    Vora SA; Wong WW; Schild SE; Ezzell GA; Halyard MY
    Int J Radiat Oncol Biol Phys; 2007 Jul; 68(4):1053-8. PubMed ID: 17398023
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Excellent results from high dose rate brachytherapy and external beam for prostate cancer are not improved by androgen deprivation.
    Demanes DJ; Brandt D; Schour L; Hill DR
    Am J Clin Oncol; 2009 Aug; 32(4):342-7. PubMed ID: 19398902
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Radiation therapy for prostate cancer].
    Sumi M
    Nihon Rinsho; 2005 Feb; 63(2):279-85. PubMed ID: 15714979
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Acute toxicity of conformal high dose interstitial brachytherapy boost in prostate cancer.
    Soumarová R; Homola L; Stursa M; Perková H
    Neoplasma; 2006; 53(5):410-7. PubMed ID: 17013535
    [TBL] [Abstract][Full Text] [Related]  

  • 18. 192Ir or 125I prostate brachytherapy as a boost to external beam radiotherapy in locally advanced prostatic cancer: a dosimetric point of view.
    Nickers P; Thissen B; Jansen N; Deneufbourg JM
    Radiother Oncol; 2006 Jan; 78(1):47-52. PubMed ID: 16216365
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Biological effective dose for comparison and combination of external beam and low-dose rate interstitial brachytherapy prostate cancer treatment plans.
    Jani AB; Hand CM; Lujan AE; Roeske JC; Zagaja GP; Vijayakumar S; Pelizzari CA
    Med Dosim; 2004; 29(1):42-8. PubMed ID: 15023392
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Use of benchmark dose-volume histograms for selection of the optimal technique between three-dimensional conformal radiation therapy and intensity-modulated radiation therapy in prostate cancer.
    Luo C; Yang CC; Narayan S; Stern RL; Perks J; Goldberg Z; Ryu J; Purdy JA; Vijayakumar S
    Int J Radiat Oncol Biol Phys; 2006 Nov; 66(4):1253-62. PubMed ID: 17145540
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 21.